- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Vogenx passt nach Börsengang Satzung und Geschäftsordnung an | 3 | Investing.com Deutsch | ||
| Do | Vogenx, Inc.: Vogenx Announces Closing of Initial Public Offering | 212 | ACCESS Newswire | RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for... ► Artikel lesen | |
| VOGENX Aktie jetzt für 0€ handeln | |||||
| Do | Vogenx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| Mi | Metabolic disorders biotech Vogenx prices IPO at $13, the high end of the range | 1 | Renaissance Capital | ||
| Mi | Vogenx prices IPO at $13 per share, expects to raise $81.3M | 2 | Seeking Alpha | ||
| Mi | Vogenx prices IPO at $13 per share, expects $81.3M proceeds | 1 | Investing.com | ||
| Mi | Vogenx, Inc.: Vogenx Announces Pricing of Initial Public Offering | 531 | ACCESS Newswire | RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for... ► Artikel lesen | |
| Mo | Vogenx, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| Mo | Vogenx, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 30.07. | Attovia, Braveheart Bio and Vogenx seek more than $500M across trio of IPOs | 1 | FierceBiotech | ||
| 30.07. | Metabolic disorders biotech Vogenx sets terms for $75 million IPO | 1 | Renaissance Capital | ||
| 29.07. | Vogenx, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 20.07. | BlossomHill, VogenX and Latigo reveal IPO plans | 1 | pharmaphorum | ||
| 16.07. | Vogenx joins the IPO queue to fund phase 2-stage metabolic drug | 2 | FierceBiotech | ||
| 16.07. | Metabolic disorders biotech Vogenx files for a US IPO | 1 | Renaissance Capital | ||
| 15.07. | Vogenx, Inc. - S-1, General form for registration of securities | 4 | SEC Filings |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,660 | +1,67 % | Märkte am Morgen: Gold, SanDisk, eBay, Alphabet, Deutsche Telekom, Qiagen | Der DAX hat in dieser Woche bisher jeden Tag ein neues Rekordhoch markiert - so auch gestern. 26.403 Punkte lautet die Marke, die wir uns merken müssen. Wie lange, wird sich zeigen. Gestern gab es jedenfalls... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,000 | 0,00 % | H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics | ||
| APOGEE THERAPEUTICS | 134,44 | -0,08 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,830 | -1,71 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SEPTERNA | 45,140 | -6,33 % | Septerna, Inc.: Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results | Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 19,640 | +0,20 % | Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,650 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 368,69 | -4,57 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 25,930 | -0,92 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| BEAM THERAPEUTICS | 26,500 | -1,30 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| JANUX THERAPEUTICS | 16,000 | -4,02 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| COGENT BIOSCIENCES | 37,300 | -4,31 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| ARRIVENT BIOPHARMA | 30,000 | -4,64 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to... ► Artikel lesen | |
| EVOTEC | 3,548 | -7,84 % | EQS-News: Evotec SE: Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen
06.08.2026... ► Artikel lesen | |
| IMMUNOVANT | 41,810 | -1,85 % | Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress |
VOGENX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 14,090 Euro und damit +8,38 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOGENX INC finden Sie auf Wallstreet Online.